First-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in head and neck cancers: An additional cohort of the phase 1 SURPASS trial Meeting Abstract
| Authors: | Ho, A.; Garcia-Consuegra, A.; Saro, J.; Sauer, A.; Cristiani, S.; Brophy, F. E.; Streets, S.; Norry, E.; Gillison, M.; Charlson, J.; Bover, M.; Zugazagoitia, J.; Calvo, E.; Ugidos, L.; Bruixola, G.; Garcia, V. M.; Hong, D. S.; Rubio-Pérez, J.; Aggen, D. H. |
| Abstract Title: | First-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in head and neck cancers: An additional cohort of the phase 1 SURPASS trial |
| Meeting Title: | 2024 Multidisciplinary Head and Neck Cancers Symposium |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 118 |
| Issue: | 5 |
| Meeting Dates: | 2024 Feb 29-Mar 2 |
| Meeting Location: | Phoenix, AZ |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-04-01 |
| Start Page: | e84 |
| End Page: | e85 |
| Language: | English |
| DOI: | 10.1016/j.ijrobp.2024.01.187 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting Abstract: 252 -- Accession Number: 175934852 -- Entry Date: In Process -- Revision Date: 20240313 -- Publication Type: Journal Article -- Journal Subset: Biomedical; Peer Reviewed; USA -- NLM UID: 7603616. -- Source: CINAHL Plus with Full Text |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work